Exhibit 10.36

​

SUPPLEMENT

​

This Supplement (this “Supplement”) to License Agreement by and between Ocular Therapeutix, Inc. and Affamed Therapeutics Limited is made and entered into as of January 18, 2021.

​

WHEREAS, Ocular Therapeutix, Inc. (“Ocular”) and Affamed Therapeutics Limited (“Affamed”) entered into a License Agreement dated as of October 28, 2020 (the “License Agreement”); and

​

WHEREAS, Ocular and Affamed desire to supplement the License Agreement by adding a reference to two patents to Exhibit A to the License Agreement;

​

NOW THEREFORE, the Parties agree as follows:

​

1.All terms used in this Supplement and not defined shall have the meanings ascribed to them in the License Agreement.

​

2.Exhibit A is supplemented by adding the following:

​

·KR20190057353A

·CN102395401B

​

3.Except as supplemented hereby, each of the terms and provisions of the License Agreement shall remain in full force and effect.

​

4.This Supplement may be executed in counterparts, all of which taken together shall be regarded as one and the same instrument.

​

​

​

IN WITNESS WHEROF, the Parties have executed this Supplement through their duly authorized representatives to be effective as of the Effective Date.

​

​